Suppr
超能文献

Generalized prurigo nodularis after dermatomal herpes zoster: Resolution with nemolizumab.

作者信息

Fason Claire, Tyring Stephen

机构信息

McGovern Medical School, University of Texas Health Science Center, Houston, Texas.

Department of Dermatology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas.

出版信息

JAAD Case Rep. 2025 Apr 14;60:122-125. doi: 10.1016/j.jdcr.2025.04.001. eCollection 2025 Jun.

DOI:10.1016/j.jdcr.2025.04.001

PMID:40491521

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12146484/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17bc/12146484/24dabdf18740/gr1.jpg

相似文献

Generalized prurigo nodularis after dermatomal herpes zoster: Resolution with nemolizumab.

JAAD Case Rep. 2025 Apr 14;60:122-125. doi: 10.1016/j.jdcr.2025.04.001. eCollection 2025 Jun.

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.

Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.

Trans R Soc Trop Med Hyg. 2011 Jul;105(7):401-4. doi: 10.1016/j.trstmh.2011.04.001. Epub 2011 May 28.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.

Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.

Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.

Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.

Br J Dermatol. 2024 Jul 16;191(2):200-208. doi: 10.1093/bjd/ljae131.

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis.

Skin Therapy Lett. 2025 May;30(3):1-3.

A critical evaluation of nemolizumab for prurigo nodularis.

Expert Rev Clin Immunol. 2024 Jun;20(6):577-587. doi: 10.1080/1744666X.2024.2306225. Epub 2024 Jan 19.

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1820-1825. doi: 10.1111/jdv.18377. Epub 2022 Jul 4.

Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.

J Allergy Clin Immunol. 2022 Apr;149(4):1329-1339. doi: 10.1016/j.jaci.2021.10.004. Epub 2021 Nov 29.

本文引用的文献

Serum Inflammatory Cytokine Levels in Herpes Zoster Patients and Their Association with Postherpetic Neuralgia: A Prospective Study.

Med Sci Monit. 2023 Oct 30;29:e941878. doi: 10.12659/MSM.941878.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.

Patient Perspectives on Living With Severe Prurigo Nodularis.

JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251.

IL-31 expression in HIV-infected patients with different routes of disease transmission.

Medicine (Baltimore). 2022 Jun 24;101(25):e29509. doi: 10.1097/MD.0000000000029509.

Prurigo nodularis: Pathogenesis and management.

J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.

Prurigo nodularis: Epidemiology and clinical features.

J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.

Breaking the Itch-Scratch Cycle in Prurigo Nodularis.

N Engl J Med. 2020 Feb 20;382(8):757-758. doi: 10.1056/NEJMe1916733.

Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.

Trans R Soc Trop Med Hyg. 2011 Jul;105(7):401-4. doi: 10.1016/j.trstmh.2011.04.001. Epub 2011 May 28.

Prurigo nodularis in healed herpes zoster scar: an isotopic response.

J Eur Acad Dermatol Venereol. 2007 May;21(5):711-2. doi: 10.1111/j.1468-3083.2006.02007.x.

Clinical manifestations of varicella-zoster virus infection.

Dermatol Clin. 2002 Apr;20(2):267-82. doi: 10.1016/s0733-8635(01)00012-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Generalized prurigo nodularis after dermatomal herpes zoster: Resolution with nemolizumab.

JAAD Case Rep. 2025 Apr 14;60:122-125. doi: 10.1016/j.jdcr.2025.04.001. eCollection 2025 Jun.

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.

Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.

Trans R Soc Trop Med Hyg. 2011 Jul;105(7):401-4. doi: 10.1016/j.trstmh.2011.04.001. Epub 2011 May 28.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.

Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.

Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.

Br J Dermatol. 2024 Jul 16;191(2):200-208. doi: 10.1093/bjd/ljae131.

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis.

Skin Therapy Lett. 2025 May;30(3):1-3.

A critical evaluation of nemolizumab for prurigo nodularis.

Expert Rev Clin Immunol. 2024 Jun;20(6):577-587. doi: 10.1080/1744666X.2024.2306225. Epub 2024 Jan 19.

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1820-1825. doi: 10.1111/jdv.18377. Epub 2022 Jul 4.

Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.

J Allergy Clin Immunol. 2022 Apr;149(4):1329-1339. doi: 10.1016/j.jaci.2021.10.004. Epub 2021 Nov 29.

本文引用的文献

Serum Inflammatory Cytokine Levels in Herpes Zoster Patients and Their Association with Postherpetic Neuralgia: A Prospective Study.

Med Sci Monit. 2023 Oct 30;29:e941878. doi: 10.12659/MSM.941878.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.

Patient Perspectives on Living With Severe Prurigo Nodularis.

JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251.

IL-31 expression in HIV-infected patients with different routes of disease transmission.

Medicine (Baltimore). 2022 Jun 24;101(25):e29509. doi: 10.1097/MD.0000000000029509.

Prurigo nodularis: Pathogenesis and management.

J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.

Prurigo nodularis: Epidemiology and clinical features.

J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.

Breaking the Itch-Scratch Cycle in Prurigo Nodularis.

N Engl J Med. 2020 Feb 20;382(8):757-758. doi: 10.1056/NEJMe1916733.

Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.

Trans R Soc Trop Med Hyg. 2011 Jul;105(7):401-4. doi: 10.1016/j.trstmh.2011.04.001. Epub 2011 May 28.

Prurigo nodularis in healed herpes zoster scar: an isotopic response.

J Eur Acad Dermatol Venereol. 2007 May;21(5):711-2. doi: 10.1111/j.1468-3083.2006.02007.x.

Clinical manifestations of varicella-zoster virus infection.

Dermatol Clin. 2002 Apr;20(2):267-82. doi: 10.1016/s0733-8635(01)00012-2.

Suppr超能文献

Generalized prurigo nodularis after dermatomal herpes zoster: Resolution with nemolizumab.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译